Does Rallies show Form 4 insider transactions for PVLA?

Yes. Rallies tracks PVLA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PVLA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PVLA. It does not provide personalized investment advice.

PVLA (Palvella Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Palvella Therapeutics, Inc. Common Stock (PVLA) is a publicly traded Healthcare sector company. As of May 21, 2026, PVLA trades at $115.50 with a market cap of $1.51B and a P/E ratio of -30.54. PVLA moved +5.56% today. Year to date, PVLA is +30.60%; over the trailing twelve months it is +397.20%. Its 52-week range spans $11.17 to $151.18. Analyst consensus is strong buy with an average price target of $231.00. Rallies surfaces PVLA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PVLA stock inside the company?

Recent PVLA insider activity includes Goin Kathleen sold 1.50K, Goin Kathleen sold 1.50K, Goin Kathleen sold 561, Goin Kathleen sold 639, and Goin Kathleen sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PVLA Key Metrics

Key financial metrics for PVLA
Metric	Value
Price	$115.50
Market Cap	$1.51B
P/E Ratio	-30.54
EPS	$-3.71
Dividend Yield	0.00%
52-Week High	$151.18
52-Week Low	$11.17
Volume	0
Avg Volume	0
Revenue (TTM)	$2.59M
Net Income	$-41.72M
Gross Margin	0.00%

Recent PVLA Insider Trades

Goin Kathleen sold 1.50K (~$189.20K) on Apr 15, 2026.
Goin Kathleen sold 1.50K (~$190.69K) on Apr 15, 2026.
Goin Kathleen sold 561 (~$71.94K) on Apr 15, 2026.
Goin Kathleen sold 639 (~$82.54K) on Apr 15, 2026.
Goin Kathleen sold 100 (~$13.03K) on Apr 15, 2026.

Latest PVLA News

Palvella’s QTORIN Rapamycin Delivers +2.5-Point Bleeding Score Gain in Phase 2 Trial — May 15, 2026
Palvella Therapeutics Uplists to Nasdaq Global Market After Meeting Higher Listing Standards — May 13, 2026
Palvella Raises $230M, Secures FDA Pre-NDA Meeting for QTORIN Q2 — May 7, 2026
Palvella to present significant Phase 3 SELVA and Phase 2 TOIVA rapamycin data on May 20 — Apr 20, 2026
Palvella Names John D. Doux to Board to Advance QTORIN™ Rare Disease Pipeline — Apr 13, 2026

PVLA Analyst Consensus

14 analysts cover PVLA: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $231.00.

Common questions about PVLA

Who is trading PVLA stock inside the company?: Recent PVLA insider activity includes Goin Kathleen sold 1.50K, Goin Kathleen sold 1.50K, Goin Kathleen sold 561, Goin Kathleen sold 639, and Goin Kathleen sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PVLA?: Yes. Rallies tracks PVLA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PVLA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PVLA. It does not provide personalized investment advice.